New York, NY and Cambridge, MA – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial.

AMVUTTRA is an FDA-approved RNAi therapeutic for the treatment of ATTR amyloidosis, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the nerves, heart and GI tract.

AMVUTTRA received FDA approval for the treatment of TTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025 and for hereditary TTR amyloidosis with polyneuropathy (hATTR-PN) in 2022. ATTR-CM represents a fast-growing category driven by new therapeutic options and improving diagnosis rates. There are approximately 30,000 hATTR-PN patients globally and more than 300,000 ATTR-CM patients globally, of which just 20% are currently diagnosed. AMVUTTRA sales reached approximately $1 billion in 2024, which represented 74% year-over-year growth, and are projected to exceed $6 billion by 2028 based on analyst consensus.

Transaction Terms
Royalty Pharma has acquired Blackstone’s 1% royalty on worldwide net sales of AMVUTTRA in exchange for an upfront payment of $310 million. The royalty duration for AMVUTTRA will extend through March 2035. The transaction is expected to deliver returns consistent with Royalty Pharma’s stated targets for approved products under a range of scenarios that factor in significant potential competition from Alnylam’s follow-on product, nucresiran. The transaction with Royalty Pharma is for AMVUTTRA sales beginning on October 1, 2025 and excludes the fixed payments paid to Blackstone as part of the original transaction in which Blackstone invested $70 million.

Advisors
Gibson Dunn, Dechert and Maiwald acted as legal advisors to Royalty Pharma. Ropes & Gray and TD Securities acted as advisors to Blackstone.

About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.

About Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $12 billion in assets under management.

Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com

Blackstone
David Vitek
(212) 583-5291
David.Vitek@blackstone.com